What you missed in March: the state of biotech, the impact of NIH funding cuts, and more

Get 25% off an annual STAT+ subscription and read more of our award-winning journalism.

My Account    STAT+ Check out last month's top stories. If you like what you see, join the STAT+ community today – and enjoy 25% off your first year with code LOYAL25. Molly Ferguson/STAT 1   The numbers that tell a scary story about the state of biotech By Adam Feuerstein Adobe 2   At NIH, 'everyone is on edge' as they brace for deep cuts and more centralized control By Jonathan Wosen, Megan Molteni, Jason Mast, Angus Chen, Lev Facher, and Anil Oza Wikimedia Commons 3   NIH cancels funding for landmark diabetes study at a time of focus on chronic disease By Elaine Chen 25% off STAT+ Get 25% off your first year of STAT+ with discount code LOYAL25. SUBSCRIBE NOW More Top Stories 4   Cancer research, long protected, feels 'devastating' effects under Trump By Angus Chen 5   HHS emergency response unit given two days to figure out its fate By Sarah Owermohle 6   NIH terminates ongoing grants for LGBTQ+ research By Angus Chen 7   Hours after NIH director confirmed, the agency tackles one of his priorities — ending 'censorship' in science By Anil Oza 8   As GLP-1 compounding stares down a wall, telehealth companies pivot to hormones By Katie Palmer 9   Eric Green is out as head of National Human Genome Research Institute By Megan Molteni, Anil Oza, Jason Mast, Matthew Herper, and Lizzy Lawrence 10   Tara Schwetz, who oversaw creation of ARPA-H, placed on leave by NIH By Lev Facher read more STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails Update Newsletter Preferences • Contact Us • Advertise with Us